Agent | Response rate (%) |
Paclitaxel | 34–41 |
Irinotecan | 47# |
Topotecan | 39 |
Docetaxel | 28# |
Gemcitabine | 26 |
Vinorelbine | 12.5# |
Bendamustine | 72.7% first-line in combination with carboplatin |
Amrubicin | 21.3# (refractory patients), 44# (sensitive patients) |
#: previously treated patients only.